BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37886451)

  • 1. Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia.
    Petgrave YP; Selukar S; Epperly R; Naik S; Santos ND; Triplett BM; Gottschalk S; Bissler J; Talleur AC
    Res Sq; 2023 Oct; ():. PubMed ID: 37886451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.
    Gutgarts V; Jain T; Zheng J; Maloy MA; Ruiz JD; Pennisi M; Jaimes EA; Perales MA; Sathick J
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1071-1076. PubMed ID: 32088364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
    Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
    Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy.
    Maron GM; Hijano DR; Epperly R; Su Y; Tang L; Hayden RT; Naik S; Karol SE; Gottschalk S; Triplett BM; Talleur AC
    Front Oncol; 2022; 12():845540. PubMed ID: 35356197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.
    Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies.
    Shalabi H; Martin S; Yates B; Wolters PL; Kaplan C; Smith H; Sesi CR; Jess J; Toledo-Tamula MA; Struemph K; Delbrook CP; Khan OI; Mackall CL; Lee DW; Shah NN
    Neuro Oncol; 2022 Sep; 24(9):1584-1597. PubMed ID: 35148417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
    Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).
    Tasian SK; Gardner RA
    Ther Adv Hematol; 2015 Oct; 6(5):228-41. PubMed ID: 26425336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
    He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
    [No Abstract]   [Full Text] [Related]  

  • 10. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy.
    Farooqui N; Sy-Go JPT; Miao J; Mehta R; Vaughan LE; Bennani NN; Wang Y; Bansal R; Hathcock MA; Hayman SR; Johnston PB; Villasboas JC; Paludo J; Ansell SM; Leung N; Lin Y; Herrmann SM
    Mayo Clin Proc; 2022 Jul; 97(7):1294-1304. PubMed ID: 35787856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
    Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
    Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
    Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
    Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
    Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
    Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
    Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
    Yoo JW
    Blood Res; 2023 Apr; 58(S1):S20-S28. PubMed ID: 36891576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 20. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.